Clinical trials: Botox Injection
Spasticity
ETREAT Study on Effectiveness of Botulinum Toxin Type A Injections to Treat Post-stroke Upper and/or Lower Limb Spasticity
The objective of this study is to evaluate the effectiveness of BoNT-A on functional improvement in patients with post-stroke upper and/or lower limb spasticity in the early stage of spasticity development, according to routine…
- Trial name
- ETREAT (NCT02275312)
- Where
- 17 sites in Spain
- Volunteers
- 110 people
- Sponsor
- Ipsen
Blepharospasm
Study of a Single Administration of 3 Doses of Dysport® for the Treatment of Benign Essential Blepharospasm
The purpose of this study is to compare the effectiveness of 3 doses of Dysport® with placebo by assessing functional disability in blepharospasm.
- Trial name
- NCT00234507
- Testing
- Botulinum toxin type A
- Where
- 14 sites in United States
- Volunteers
- 120 people
- Sponsor
- Ipsen
Nervous System Disorders
Dysport® Adult Upper Limb Spasticity Extension Study
The purpose of this research study is to assess the long term safety of Dysport® in hemiparetic subjects with upper limb spasticity due to stroke or traumatic brain injury over repeated treatment cycles.
- Trial name
- NCT01313312
- Testing
- Botulinum toxin type A
- Where
- 34 sites in United States, Belgium and 7 more
- Volunteers
- 258 people
- Sponsor
- Ipsen
Upper Limb Spasticity
Study of Intramuscular Injections of ABBV-950 to Assess Adverse Events and Change in Disease Activity in Adult Participants With Upper Limb Spasticity
Spasticity is often observed as muscle tightness and stiffness in the upper and/or lower limbs. Upper limb spasticity can interfere with joint movement and its severity can range from mild to severe.
- Trial name
- NCT05956509
- Testing
- ABBV-950, BOTOX
- Where
- 9 sites in United States
- Volunteers
- 1 people
- Sponsor
- AbbVie
Glabellar Frown Lines
Efficacy and Safety of DaxibotulinumtoxinA for Injection to Treat Moderate to Severe Glabellar Lines
This is a safety and efficacy study of DaxibotulinumtoxinA for Injection to treat moderate to severe frown lines.
- Trial name
- NCT03014635
- Testing
- Botulinum Toxins, Type A
- Where
- 14 sites in United States, Canada
- Volunteers
- 306 people
- Sponsor
- Revance Therapeutics, Inc.
Masseter Muscle Prominence
A Study to Assess BOTOX Injections for the Change of Masseter Muscle Prominence in Adult Participants
The masseter muscle is one of the muscles in the lower face used for chewing. The prominence of the masseter muscle can appear as a widened lower face which some individuals deem as aesthetically undesirable and can be treated by…
- Trial name
- MMP US P3 417 (NCT06399718)
- Testing
- BOTOX
- Where
- 20 sites in United States
- Volunteers
- 207 people
- Sponsor
- AbbVie
Forehead Lines
A Study to Assess Adverse Events and Effectiveness of OnabotulinumtoxinA Intramuscular Injections for the Change of Moderate to Severe Forehead Lines in Adult Participants
Facial lines that develop from repeated facial expression, such as forehead lines (FHL), are typically treated by selectively weakening specific muscles with small quantities of botulinum toxin.
- Trial name
- NCT06794866
- Testing
- OnabotulinumtoxinA
- Where
- 15 sites in Japan
- Volunteers
- 150 people
- Sponsor
- AbbVie
Wrinkles
Study of BOTOX and JUVEDERM for Treatment of Moderate to Severe Facial Wrinkles and Folds
The purpose of this study is to see how well Juvederm Ultra XC or Juvederm Ultra Plus XC, and BOTOX Cosmetic, work compared to each other and when used together for the cosmetic treatment of age-associated wrinkles and folds of…
- Trial name
- JUVE_BTX (NCT01269801)
- Testing
- onabotulinumtoxinA, JUVÉDERM
- Where
- 3 sites in United States, Canada
- Volunteers
- 156 people, healthy volunteers welcome
- Sponsor
- AboutSkin Dermatology and DermSurgery, PC
Moderate to Severe Glabellar Lines
A Phase III Study to Evaluate the Efficacy and Safety of Recombinant Botulinum Toxin Type A for Injection in the Treatment of Moderate to Severe Glabellar Lines
This is a randomized, double-blind, placebo- and active-controlled parallel-group multi-center phase III study to evaluate the efficacy and safety of Rcombinant botulinum neurotoxin type A for injection (YY001)) in the treatment…
- Trial name
- NCT06499688
- Testing
- Rcombinant botulinum neurotoxin type A for injection (YY001), OnabotulinumtoxinA
- Where
- 16 sites in China
- Volunteers
- 529 people
- Sponsor
- Chongqing Claruvis Pharmaceutical Co., Ltd.
Post-Stroke Chronic Upper Limb Spasticity
Effectiveness and Safety of SMART [Spastic Muscle Palpation by Anatomic Landscape for BoNT-A (Botulinumtoxin-A) Injection to Reduce Muscle Tone] BoNT-A Therapy With Dysport® in Patients With Post-stroke Chronic Upper Limb Spasticity (ULS) in Real-life Setting.
The purpose of this study is to collect data for Dysport® SMART BoNT-A therapy usage in an office-based setting in post-stroke participants with chronic (> 6 months) focal Upper Limb Spasticity who have been under stable oral…
- Trial name
- SMART-NIS (NCT05224349)
- Where
- 31 sites in Germany
- Volunteers
- 121 people
- Sponsor
- Ipsen
Upper Limb Spasticity Unilaterally in Adults With History of Stroke, Increased Muscle Tone in Elbow, Wrist, Finger, and Thumb Flexors.
ASIS for Botox in Upper Limb Spasticity
Botox act on nerve endings, yet there are no nerve endings inside the muscle, where they are typically injected. All nerves terminate on the fascia, where ASIS device can precisely deliver Botox by creating that subdermal…
- Trial name
- ASISinULS (NCT02074150)
- Testing
- Gadolinium, Efficacy of Botox intramuscularly at Week 6, Efficacy of Botox intramuscularly at Week 12,
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- li nguyen
Overactive Bladder Syndrome
Use of Repris Needle in Bladder Injection
Treatment of overactive bladder (OAB) has been treated successfully by the injection of Botox. The Repris injection needle has a deflection that may assist in injection difficult to reach with standard straight needles.
- Trial name
- NCT04982120
- Testing
- Repris Needle
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Uro-1 Medical
Facial Corrections, Facial Lines
A Study to Evaluate Satisfaction in Adult Participants With the Aesthetics of the Periorbital Area After JUVÉDERM® Fillers and BOTOX®/VISTABEL® Injections
Different studies have shown the negative effects of aging around the area of the eyes. Signs of aging may contribute to erroneously projected emotions (e.g., anger, tiredness, or sadness) that do not reflect the individual's…
- Trial name
- NCT05647551
- Testing
- BOTOX®/VISTABEL®, Juvéderm® VOLBELLA® with Lidocaine, Juvéderm® VOLIFT® with Lidocaine
- Where
- 8 sites in Australia, Belgium
- Volunteers
- 73 people
- Sponsor
- AbbVie
Spasticity
Study on the Use of Botulinum Toxin Type A in the Treatment of Chronic Post-stroke Spastic Patients
The purpose of this study is to document the effectiveness of treating chronic post-stroke spastic patients with Botulinum Toxin type A.
- Trial name
- B-CAUSE (NCT02390206)
- Where
- 11 sites in Brazil
- Volunteers
- 239 people
- Sponsor
- Ipsen
Upper Facial Lines
A Study to Evaluate Participant Satisfaction and Natural Outcomes Following Administration of BOTOX Cosmetic Injections in Adult Participants for Treatment of Upper Facial Lines
Facial lines that develop from repeated facial expression, such as glabellar lines (GL), lateral canthal lines (LCL), and forehead lines (FHL), are typically treated by selectively weakening specific muscles with small quantities…
- Trial name
- UFL BOND 974 (NCT06218251)
- Testing
- BOTOX
- Where
- 10 sites in United States, Canada
- Volunteers
- 100 people
- Sponsor
- AbbVie
Upper Limb Spasticity
A Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in Multiple Treatments of Adult Upper Limb Spasticity
This is an open-label, multicenter, phase III clinical study to evaluate the long-term safety and efficacy of multiple treatments with recombinant botulinum toxin type A (YY001) for injection in adult upper limb spasticity
- Trial name
- NCT07478822
- Testing
- Recombinant botulinum toxin type A for injection (YY001)
- Where
- 16 sites in China
- Volunteers
- 300 people
- Sponsor
- Chongqing Claruvis Pharmaceutical Co., Ltd.
Glabellar Lines
A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines
This is a Phase 2, dose ranging study to evaluate the safety of OnabotulinumtoxinA X and to compare the efficacy of OnabotulinumtoxinA X and placebo for the treatment of Glabellar Lines in adult participants with moderate to…
- Trial name
- NCT05100199
- Testing
- OnabotulinumtoxinA X
- Where
- 18 sites in United States
- Volunteers
- 328 people
- Sponsor
- Allergan
Nervous System Disorders
Dysport® Adult Upper Limb Spasticity
The purpose of this research study is to assess the efficacy of Dysport compared to placebo in improving muscle tone in hemiparetic subjects with upper limb spasticity due to stroke or traumatic brain injury.
- Trial name
- NCT01313299
- Testing
- Botulinum toxin type A
- Where
- 40 sites in United States, Belgium and 7 more
- Volunteers
- 243 people
- Sponsor
- Ipsen
Cervical Dystonia
DYSPORT™ Clinical & Health Economics Outcomes Registry in Cervical Dystonia
The purpose of the protocol is to determine typical patient response to Dysport in the treatment of adult cervical dystonia (CD).
- Trial name
- ANCHOR-CD (NCT01314365)
- Where
- 45 sites in United States
- Volunteers
- 350 people
- Sponsor
- Ipsen
Cervical Dystonia
Open Label Safety/Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) in Patients With Cervical Dystonia
Open label study to evaluate the safety and immunogenicity of MYOBLOC (Botulinum Toxin Type B) in adult patients with a clinical diagnosis of Cervical Dystonia (CD).
- Trial name
- NCT00702754
- Testing
- Botulinum Toxin Type B
- Volunteers
- 502 people
- Sponsor
- Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC